Roemer, Frank W.
Jansen, Mylène
Marijnissen, Anne C. A.
Guermazi, Ali
Heiss, Rafael
Maschek, Susanne
Lalande, Agnes
Blanco, Francisco J.
Berenbaum, Francis
van de Stadt, Lotte A.
Kloppenburg, Margreet
Haugen, Ida K.
Ladel, Christoph H.
Bacardit, Jaume
Wisser, Anna
Eckstein, Felix
Lafeber, Floris P. J. G.
Weinans, Harrie H.
Wirth, Wolfgang
Article History
Received: 24 May 2022
Accepted: 27 October 2022
First Online: 17 November 2022
Declarations
:
: The study is being conducted in compliance with the protocol, Good Clinical Practice (GCP), the Declaration of Helsinki, and the applicable ethical and legal regulatory requirements (for all countries involved), and is registered under clinicaltrials.gov nr: NCT03883568 (first submitted date 21/03/2019). All participants have received oral and written information and provided written informed consent. Ethics approval and all experimental protocols were approved by the local institutional ethics committees: Leiden University Medical Center, Leiden, The Netherlands; Complexo Hospitalario Universitario de A Coruña, A Coruña, Spain; Diakonhjemmet Hospital, Oslo; Norway; Assistance Publique—Hôpitaux de Paris, Sorbonne University, Paris France.
: Not applicable.
: The IMI-APPROACH project received a grant from Innovative Medicines Institute, grant agreement 11577.Competing interests outside the submitted work:FWR is Chief Medical Officer and shareholder of BICL, LLC. He has received consulting honoraria from Calibr and Grünenthal; MJ did not declare any conflict of interest; ACAM did not declare any conflict of interest, AG has received consultancies, speaking fees, and/or honoraria from Sanofi-Aventis, Merck Serono, and TissuGene and is President and shareholder of Boston Imaging Core Lab (BICL), LLC a company providing image assessment services; RH did not declare any conflict of interest; SM is employee and shareholder of Chondrometrics GmbH; AL is employee of Institut de Recherches Internationales Servier; FJB reports grants from Gebro Pharma, grants from BIOIBERICA, grants from AB Science, grants from Abbvie, grants from Ablynx N.V., grants from Amgen, grants from Archigen Biotech Limited, grants from Boehringer, grants from Bristol-Myers, grants from Celgene Int., grants from Eli Lilly and Company, grants from F. Hoffmann- La Roche, grants from Galapagos, grants from Gedeon, grants from Genentech, grants from Gideal Sciences, NC, grants from Glaxosmithkline, grants from Hospira, grants from INC Research UK, grants from Inventiv Health Clinical, grants from Janssen, grants from Lilly, grants from Nichi-IKO Pharmaceutical, grants from Novartis, grants from ONO Pharma, grants from Pfizer, grants from Pharmaceutical Research, grants from Regeneron, grants from Roche, grants from SA UCB Pharma, grants from Sanofi, grants from TRB Chemedica, grants from UCB Biosciences GMBH, outside the submitted work; In addition, FJB has a patent Molecular block-matching method for gel image analysis issued, a patent Targeting A Specific Receptor On Cells With A Specific Compound For Use In The Treatment And/Or The Prevention Of Osteoarthritis And Rheumatoid Arthritis pending, a patent Genetic markers for osteoarthritis issued, a patent Method for the diagnosis of osteoarthritis issued, a patent Genetic markers for osteoarthritis pending, a patent Method for the diagnosing Arthrosis pending, a patent Method for diagnosing Arthrosis pending, a patent Method for the diagnosis of osteoarthritis pending, and a patent Anti-connexin compounds for use in the prevention and/or treatment of degenerative joint diseases. pending; FB reports personal fees from Boehringer, Bone Therapeutics, Expanscience, Galapagos, Gilead, GSK, Merck Sereno, MSD, Nordic, Novartis, Pfizer, Regulaxis, Roche, Sandoz, Sanofi, Servier, UCB, Peptinov, TRB Chemedica, 4P Pharma; LAvdS did not declare any conflict of interest; MK reports grants from IMI-APPROACH, grants from Dutch Arthritis Association, during the conduct of the study; other from GlaxoSmithKline, Pfizer, Merck-Serono, Kiniksa, Abbvie; IKH reports personal fees from AbbVie, grants from Pfizer; CL was employee of Merck KGaA, at start of the study; JB did not declare any conflict of interest; AW is employee of Chondrometrics GmbH; FE is CEO and shareholder of Chondrometrics GmbH and received personal fees from AbbVie, Galapagos NV, HealthLink, ICM, IRIS, Kolon TissueGene, Merck KGaA, Novartis, Roche and Samumed and grants from Foundation for the NIH, University of California, San Francisco, NIH/National Heart, Lung, and Blood Institute, Bioclinica, Galapagos NV, Novartis, TissueGene, Erlangen University Hospital, University of Sydney, CALIBR, University of Basel, University of Western Ontario, Stanford University, ICM Co., Ltd., UMC Utrecht, Federal Ministry of Education and Research, Germany; FPJGL did not declare any conflict of interest; HHW did not declare any conflict of interest; WW is employee and shareholder of Chondrometrics GmbH and received consulting fees from Galapagos NV.